Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11) - Trial NCT06324188
Access comprehensive clinical trial information for NCT06324188 through Pure Global AI's free database. This phase not specified trial is sponsored by Atrial Fibrillation Network and is currently Not yet recruiting. The study focuses on Atrial Fibrillation. Target enrollment is 2312 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Atrial Fibrillation Network
Timeline & Enrollment
N/A
Jun 01, 2024
May 01, 2030
Primary Outcome
Composite of cardiovascular complications related to AF,The primary safety outcome is a composite of all-cause death and serious complications of AF therapy.
Summary
EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint
 assessment, multicenter trial (Treatment Strategy trial).
 
 The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation
 ablation in patients with atrial fibrillation (AF) and a high comorbidity burden
 (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart
 failure events) compared to usual care.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06324188
Non-Device Trial